Show simple item record

dc.contributor.authorHendriksen, IlseC. E.
dc.contributor.authorMwanga-Amumpaire, Juliet
dc.contributor.authorSeidlein, Lorenzvon
dc.contributor.authorMtove, George
dc.contributor.authorWhite, Lisa J.
dc.contributor.authorOlaosebikan, Rasaq
dc.contributor.authoret al
dc.date.accessioned2024-06-05T09:43:13Z
dc.date.available2024-06-05T09:43:13Z
dc.date.issued2012
dc.identifier.citationHendriksen, I. C., Mwanga-Amumpaire, J., Von Seidlein, L., Mtove, G., White, L. J., Olaosebikan, R., ... & Dondorp, A. M. (2012). Diagnosing severe falciparum malaria in parasitaemic African children: a prospective evaluation of plasma Pf HRP2 measurement.en_US
dc.identifier.urihttp://ir.must.ac.ug/xmlui/handle/123456789/3707
dc.description.abstractBackground: In African children, distinguishing severe falciparum malaria from other severe febrile illnesses with coincidental Plasmodium falciparum parasitaemia is a major challenge. P. falciparum histidine-rich protein 2 (PfHRP2) is released by mature sequestered parasites and can be used to estimate the total parasite burden. We investigated the prognostic significance of plasma PfHRP2 and used it to estimate the malaria-attributable fraction in African children diagnosed with severe malaria. Methods and findings: Admission plasma PfHRP2 was measured prospectively in African children (from Mozambique, The Gambia, Kenya, Tanzania, Uganda, Rwanda, and the Democratic Republic of the Congo) aged 1 month to 15 years with severe febrile illness and a positive P. falciparum lactate dehydrogenase (pLDH)-based rapid test in a clinical trial comparing parenteral artesunate versus quinine (the AQUAMAT trial, ISRCTN 50258054). In 3,826 severely ill children, Plasmadium falciparum PfHRP2 was higher in patients with coma (p=0.0209), acidosis (p,0.0001), and severe anaemia (p,0.0001). Admission geometric mean (95%CI) plasma PfHRP2 was 1,611 (1,350–1,922) ng/mL in fatal cases (n=381) versus 1,046 (991– 1,104) ng/mL in survivors (n=3,445, p,0.0001), without differences in parasitaemia as assessed by microscopy. There was a U-shaped association between log10 plasma PfHRP2 and risk of death. Mortality increased 20% per log10 increase in PfHRP2 above 174 ng/mL (adjusted odds ratio [AOR] 1.21, 95%CI 1.05–1.39, p=0.009). A mechanistic model assuming a PfHRP2independent risk of death in non-malaria illness closely fitted the observed data and showed malaria-attributable mortality less than 50% with plasma PfHRP2#174 ng/mL. The odds ratio (OR) for death in artesunate versus quinine-treated patients was 0.61 (95%CI 0.44–0.83, p=0.0018) in the highest PfHRP2 tertile, whereas there was no difference in the lowest tertile (OR 1.05; 95%CI 0.69–1.61; p=0.82). A limitation of the study is that some conclusions are drawn from a mechanistic model, which is inherently dependent on certain assumptions. However, a sensitivity analysis of the model indicated that the results were robust to a plausible range of parameter estimates. Further studies are needed to validate our findings. Conclusions: Plasma PfHRP2 has prognostic significance in African children with severe falciparum malaria and provides a tool to stratify the risk of ‘‘true’’ severe malaria-attributable disease as opposed to other severe illnesses in parasitaemic African children.en_US
dc.description.sponsorship076908 and 082541 from the Wellcome Trusten_US
dc.language.isoen_USen_US
dc.publisherPLOS Medicineen_US
dc.subjectFalciparum Malariaen_US
dc.subjectParasitaemic African Childrenen_US
dc.subjectDiagnosisen_US
dc.titleDiagnosing Severe Falciparum Malaria in Parasitaemic African Children- a Prospective Evaluation of Plasma Pf HRP2 Measurementen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record